NY Attorney General Confirms Real-Life Conspiracy Among Drug Companies
The office of the New York Attorney General and the American units of Ranbaxy Laboratories Ltd. and Teva Pharmaceutical Industries Ltd. have come to terms on a settlement involving claims that an agreement between the two Big Pharma companies restricted competition unlawfully.
Both companies agreed to pay a small fine (by comparison) of $150,000 to New York State and to cease making similar agreements in the future as part of the settlement, Reuters reported. Neither company admitted or denied the allegations, but the settlement absolves them of having to do so.
By settling, the companies have ended an investigation that was being conducted by the state into an agreement that was signed by both in 2010 to sell a generic version of Pfizer, Inc.'s cholesterol-lowering drug Lipitor in the U.S., while not horning in on the exclusivity rights of other generic drugs sold by the pharmaceutical companies. Per Reuters:
- Tags:
- clinical trials
- crime
- drugs
- Eric Schneiderman
- Food and Drug Administration (FDA)
- fraud
- generic drugs
- GlaxoSmithKline (GSK)
- healthcare
- Lipitor
- market
- Merck
- Mike Adams
- New York Attorney General (NYAG)
- Pfizer
- pharmaceutical companies
- Ranbaxy Laboratories (RL)
- Sarabjit Kour Nangra
- Teva Pharmaceutical Industries (TPI)
- Login to post comments